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100 Poster Session-IIand PFS (p 5 0.05). On multivariate analysis, pts who were in
‘‘marrow remission’’ and had adverse cytogenetics had a signifi-
cantly higher rate of disease progression (p\0.001), lower OS
(p\0.001), and lower PFS (p\0.001). De novo AML was associ-
ated with a significantly better OS and PFS. Cytogenetics and
remission status are significant predictors for outcomes after
alloSCT in pts with AML or MDS.273
A STRATEGY FOR REDUCING CD31 CONTENT OF PERIPHERAL BLOOD
PROGENITOR CELL PRODUCTS FOR MATCHED RELATED DONOR ALLO-
GRAFTS
Racquel, I.-S.D., Khaleel, A., Arabella, T., Larry, L., William, V.P.,
Donna, S.E. University of Alabama, Birmingham, AL
Acute GVHD (aGVHD) causes significant morbidity and mor-
tality after allogeneic stem cell transplantation. Stem cells col-
lected from the peripheral blood (PBSC) provide greater ease of
cell collection and faster engraftment vs marrow source stem cells.
The association of PBSC with faster engraftment is likely due to
a higher number of committed precursors in the PBSC product.
Unfortunately, PBSC grafts are associated with an increased inci-
dence and severity of aGVHD due to higher numbers of alloreac-
tive T cells. Compensatory survival benefit of the larger CD31
content in PBSC collections resulting from graft vs malignancy ef-
fect has been difficult to demonstrate, however significant ‘‘purg-
ing’’ of CD31 cells below the CD31 content of marrow source
allograft results in engraftment failure, and disease relapse. We
hypothesize that reducing CD31 cell content of PBSC grafts
that of marrow source grafts would decrease the incidence of
aGVHD without compromising engraftment. We recently re-
ported a retrospective analysis of 98 patients who received
PBSC product purged of T cells in vivo by the administration of
dexamethasone to the donor for the last 3 days of G CSF mobili-
zation. The mean CD31 and CD341 cells collected were 3.68 
108 cells/kg (sd5 2.27 108) and 8.82 106 cells/kg (sd5 5.05
106) respectively. All patients engrafted successfully and had less
acute GVHD than historical controls (19% grade II–IV at 100
days). Updated data includes 41 additional patients who achieved
comparable T cell depletion with a mean CD31 content of 3.38
107 cells/kg (sd 5 2.19  107) and mean CD 341 content of
6.98  106 cells/kg (standard deviation of 4.05  106). However,
like almost all previous studies, the CD31 content of the grafts
is highly variable. We are now conducting a phase II non-random-
ized trial under an IDE from the FDA standardizing the T cell
content of the donor PBSC product to 2.5 60.5  10 7 cells/kg,
the concentration found in marrow collections. After setting aside
a portion of the PBSC product containing 2.5 60.5  107, the re-
maining product is CD31 cell depleted using magnetic bead cell
sorting technology. This allows us to study the influence of CD31
subsets, NK cells, and other graft components in engraftment, im-
mune reconstitution, and GVHD risk. Ultimately the goal of
standardization is to create a platform for ‘‘add back’’ research
and permitting a prescriptive approach to optimizing graft
content for different clinical situations.274
PERSONALIZED DOSING OF CYCLOPHOSPHAMIDE IN THE TOTAL
BODY IRRADIATION-CYCLOPHOSPHAMIDE CONDITIONING REGIMEN:
A PHASE II TRIAL IN PATIENTS WITH HEMATOLOGIC MALIGNANCY
McDonald, G.B., Guthrie, K.A., Batchelder, A., Witherspoon, R.,
McCune, J.S. Fred Hutchinson Cancer Research Center, Seattle, WA
Total body irradiation and cyclophosphamide (CY) conditioning
may cause regimen-related toxicity and mortality because of highly
variable metabolism of CY. The metabolite carboxyethylphosphor-
amide mustard (CEPM) is a reporter molecule for toxins derived
from CY. We tested the hypothesis that personalized CY dosing
would result in less liver and kidney toxicity, compared to
weight-based CY dosing (2  60 mg/kg), without affecting the
relapse rate.
Methods: We personalized the dose of CY for 50 patients receiv-
ing TBI 12 Gy using therapeutic drug monitoring with Bayesianparameter estimation after the first CY dose, to adjust the second
CY dose before allogeneic transplant (Clin Cancer Res
2006;12:4888–98). The target exposure to CEPM was 325 6 25
mM$hr. Concurrent allograft patients (N 5 100) who were condi-
tioned with TBI 12 Gy and CY 120 mg/kg served as controls.
Study endpoints were peak bilirubin levels, acute kidney injury
(doubling baseline Cr), and relapse/survival using proportional
hazards regression models.
Results: All patients on a personalized CY dosing protocol
received a first CY dose of 45 mg/kg. The mean second CY dose
was 66 mg/kg (range, 0–100 mg/kg), and the mean total CY dose
was 111 mg/kg (range, 45–145 mg/kg). There were 15 patients
whose total CY dose exceeded 120 mg/kg. The mean total AUC-
CEPM was 302 mM$hr (median 301, range 136–442 mM$hr).
The average percent deviation of the observed AUC-CEPM
from our target of 325 mM$hr was -7%. Peak total bilirubin was
significantly lower with personalized CY dosing than with stan-
dard dosing (median 1.3 mg/dL, range 0.7 – 8.8) vs. 1.7 mg/dL,
range 0.4 – 18.3), p 5 0.03. The hazard of kidney injury was re-
duced by 38% with personalized CY dosing (p 5 0.03); high bili-
rubin levels were associated with kidney injury (p 5 0.003).
Despite a lower total CY dose for most patients, personalized
CY dosing was not associated with worse relapse or survival out-
comes for the study cohort as a whole, or when analyzed as sub-
groups (by myeloid vs. lymphoid malignancy and by risk of
relapse after transplant).
Conclusions: Bayesian therapeutic drug monitoring and person-
alized CY dosing reduces extreme variability in CY metabolism in
the TBI/CY regimen, resulting in less liver and kidney injury,
compared to standard CY dosing, with no difference in relapse or
survival.275
PROSPECTIVE RANDOMIZED STUDY COMPARING NON MYELOABLA-
TIVE (FLU-TBI) AND REDUCED INTENSITY (FLU-BU-ATG) CONDITION-
ING FOR HEMATOLOGICAL MALIGNANCIES: A MULTICENTER ITAC
STUDY
Blaise, D.1, Furst, S.1, Bay, J.O.2, Faucher, C.1, Michallet, M.3,
Boiron, J.M.4, Cahn, J.Y.5, Mohty, M.6 1 Institut Paoli-Calmettes, Mar-
seille, France; 2Centre Jean Perrin, Clermont Ferrand, France; 3Hopital
Edouard Herriot, Lyon, France; 4EFS Aquitaine Limousin, Bordeaux,
France; 5CHU, Grenoble, France; 6Hotel Dieu, Nantes, France
Reduced intensity conditionings (RIC) have been introduced 10
years ago. However no definitive data exist defining the optimal
myeloablative and/or immunosuppressive association. We report
the first prospective comparison between 2 popular regimens based
on reduced intensity or non-myeloablative approaches. Flu-
Bu-ATG (Study A) associated Fludarabine (30mg/m2/5 days),
Oral Busulfan (8 mg/kg over 2 days) and Thymoglobuline (2.5
mg/m2/1day). Fluda-TBI (Study B) consisted of Fludarabine
(25mg/m2/ 3 days) and 2 Gy TBI. This program included two ran-
domized phase 2 clinical trials according to a phase 2 selection de-
sign (Liu, 1993 and 2001). Primary endpoint was one-year overall
survival (OS). Stopping rules included excessive engraftment fail-
ure and transplant related mortality ratio. Inclusion criteria were
patients presenting a hematological malignancy, non eligible for
myeloablative allo SCT, aged between 18 and 65, with a suitable
HLA identical sibling. First patient was included in January
2003. A total of 144 patients were randomized, and 137 patients
(Group A: N 5 71; group B: N 5 66) were documented in the da-
tabase for this abstract. In all, groups were well balanced for patient
characteristics; Median age 55 (32–66); Male gender: 63%; Diag-
nosis: acute leukemia: 18%; NHL: 23%; MM: 41%; Others:
18%; Disease status: CR5 29%; PR and stable disease5 63%; re-
fractory disease: 8%. Graft failure were documented in 4 patients in
group B. Cumulative incidence (CI)of aGVHD and cGVHD were
respectively of 24.4% (Group A 29.5%; Group B 19.4%) and
75.2% (Group A 77.8%; Group B 72.5%). One year TRM CI
was 18% (11–25)(Group A: 22% (11–33): group B: 15% (6–24);
p 5 NS). Overall 56% patients were alive at time of abstract
(Group A: 49%; Group B: 62%: p 5NS) for a one-year OS prob-
ability estimate of 0.75 [0.66 – 0.82] (Group A 0.73 [0.59 – 0.82];
Group B 0.78 [0.64 – 0.86]). In conclusion, this study establishes
Poster Session-II 101that, overall, these 2 regimens allows similar reduced TRM and
high one-year OS for hematological malignancies and could be se-
lected for further phase III comparison with myeloablative regi-
men. Further details of sub-group analysis (disease status; acute
leukemia, NHL and MM) will be presented in order to assess
this conclusion in specific situations with a median study follow-up
of 44 [6 – 78] months.276
APPLICATION OF SECOND GENERATION TYROSINE KINASE INHIBITORS
IN BCR-ABL POSITIVE MALIGNANCIES IN THE POST-TRANSPLANT
PERIOD
Klyuchnikov, E.1,2, Osanmaz, O.1, Schafhausen, P.3, Asenova, S.1,
Zabelina, T.1, Ayuk, F.1, Bruemmendorf, T.3, Zander, A.R.1,
Kroeger, N.1, Bacher, U.1 1University Cancer Center Hamburg
(UCCH), Hamburg, Germany; 2St. Petersburg State Pavlovs Medical
University, St.Petersburg, Russian Federation; 3University Cancer Center
Hamburg (UCCH), Hamburg, Germany
Due to the shift of allogeneic stem cell transplantation (SCT) to
poor risk cases in chronic myeloid leukemia (CML), therapy of
relapse after SCT is highly relevant. In contrast to Imatinib
(IM), where application in stem cell recipients was investigated
in many studies, studies on 2nd generation tyrosine kinase inhib-
itors (TKIs) in the post-transplantat period are limited. We
performed evaluation of 25 stem cell recipients with CML and
13 with Phil positive ALL (Phi1ALL). 9 of those pts received
2nd generation TKIs in the post-transplant period (CML blast
phase; BP: n 5 6; CML accelerated phase; AP: n 5 2; Phi1ALL;
n 5 1). There were 5 males and 4 females (median age 54 years).
Before allo-SCT, 7 were in hematological remission, 8 pts were
MRD positive. 3 pts had Imatinib resistance conferring mutations
(T315I, Y253H, L387F). All pts received unrelated SCT after
myeloablative/reduced conditioning. Indications for the post-
transplant application of dasatinib were as follows: Phi1ALL: mo-
lecular relapse: n 5 1; CML: relapse of BP: n 5 2, extramedullary
CML relapse with skeletal/cutaneous or central nervous manifes-
tations: n 5 4, refractory extramedullary manifestation: n 5 1,
persisting MRD: n 5 1. The median interval between SCT and
dasatinib was 7 months (3–19). Before start of dasatinib after
SCT, 4 cases had been refractory to imatinib. Starting dose of da-
satinib was 2  70 mg or 2  50 mg. Dose escalation was possible
in 3 pts; reduction was necessary in 1 pt. In 1 pt dasatinib was in-
terrupted due to gastrointestinal intolerance/thrombocytopenia.
Median treatment duration was 9 months (range 1–17). 3 cases
showed response to therapy: 1 pt is in stable major mol. remission,
2 other patients are in partial remission of extramedullary relapse.
1 pt suffers from meningeosis leukemica and receives intrathecal
cytarabine. Due to refractoriness, the ALL pt was transferred to
nilotinib. 4 pts (44%) died after 6, 7, 9, and 33 months from
SCT due to progression. Median overall survival after start of da-
satinib was 10 months. In conclusion, although the limited sample
has to be considered, it seems that dasatinib can be administered
with acceptable tolerance in the post-transplant period and is
able to stabilize the situation in single cases of extramedullary or
hematological relapse after SCT even in advanced disease and in
a poor-risk situation. Future prospective studies should further
evaluate the best application schedules of 2nd generation TKIs
in the post-transplant period.277
CLINICAL AND COST OUTCOMES OF DOUBLE UMBILICAL CORD BLOOD
VERSUS BONE MARROW AND PERIPHERAL BLOOD UNRELATED DONOR
HEMATOPOIETIC STEM CELL TRANSPLANTS
Lopez-Gonzalez, G.1, LeMaistre, C.F.1, Bachier, C.1, Smith, B.2,
Chan, K.W.1, Grimley, M.1, Cain, W.1, Delgado, E.1, Kaleel, S.1,
Shaughnessy, P.1 1Texas Transplant Institute, San Antonio, TX; 2Alta-
rum, San Antonio, TX
Umbilical cord blood (UCB) is a viable source of hematopoietic
stem cells (HSC) however, because of the risk of nonengraftment
with low total nucleated cell counts (TNC) per kg, double UCB
(DCB) transplants are used in larger patients (pts). We conducteda retrospective review of DCB transplants (n 5 30) from January
2004 through April 2008 compared to bone marrow (n 5 23,
30%) and peripheral blood (n 5 54, 70%) unrelated donor (UD)
transplants during the same time period. Median age was 21 yrs
(range 13–66) for DCB recipients and 45 yrs (range 0.4–67) for
UD pts. UD pts were HLA typed at A, B, C, DR, and DQ and
matched with donors at 9(10) (21%) and 10(10) (79%) loci [all
mismatches at class I alleles]. DCB recipients had HLA matches
of 6/6, 5/6/, 4/6 and 3/6 as follows: (cord 1/ cord 2): (0.0%/
6.7%), (20.0%/30.0%), (76.7%/63.3%), (3.3%/0.0%). The
median TNC/kg in DCB pts was 2.03  107 (range 7.9  106 –
9.3  108). Median day to ANC.500/ul for DCB and UD pts
was 23 days (range 6–66) and 15 days (range 7–52), and platelet
.20,000/ul was 52 days (range 7–130) and 19 days (range 9–63), re-
spectively. Incidences of acute GVHD $2 and chronic GVHD in
the UD and DCB pts were 61.0% and 51% vs. 53.3% and 45%, re-
spectively. Median follow-up was 143 days (range 12–847) for the
DCB group and 242 days (range 34–1506) for the UD pts. Esti-
mated overall survival (OS) at 1 year was 61% (95% CI: 48% to
71%) for UD pts vs. 55% (95% CI: 34% to 72%) in DCB pts
(p 5 NS). Estimated transplant related mortality (TRM) at 100
days for UD pt was 6.5% (95% CI: 2.8% to 14.9%) and 16.7%
(95% CI: 7.3% to 35.5%) (p5 0.09) in DCB pts. All facility trans-
plant related costs were reviewed from the transplant center thru
the first year post transplant, excluding pretransplant workup and
care not received at the transplant center. The total median costs
for DCB transplants were significantly more than the UD costs
at D30, D100 and 1yr post transplant by differences of $42,067,
$50,806, and $52,297, respectively (p\0.05 for each time interval).
The median length of stay for initial hospitalization at start of
preparative regimen was 22 days (2–144) in the UD pts and 29
days (6–103) in the DCB pts, and 60% of total median costs oc-
curred by D30 in the DCB group compared to 52% in the UD
group. In conclusion, DCB provides a viable option for HSC
with comparable clinical outcomes to UD transplants, however
DCB transplants are more expensive primarily because of inpatient
costs in the first 30 days.278
BUILDING AN ETHNICALLY DIVERSE CORD BLOOD INVENTORY: A
SINGLE INSTITUTION’S INITIATIVE TO INCREASE AFRICAN AMERICAN
DONATIONS
Triplett, B.1, Wofford, J.2, Mueckl, K.2, Regan, D.2, Geiler, V.2 1SSM
Cardinal Glennon Children’s Medical Center/Saint Louis University,
St. Louis, MO; 2The St. Louis Cord Blood Bank At SSM Cardinal Glen-
non Children’s Medical Center, St. Louis, MO
In 2005, the United States Congress passed the Stem Cell
Therapeutic and Research Act. A central component of this leg-
islation was the development of the National Cord Blood Inven-
tory (NCBI). A competitive bidding process was instituted and to
date three cohorts of banks have been funded with the charge to
collect and store 150,000 new cord blood units. A goal in the de-
velopment of this new inventory is to increase the number of cord
blood units from underrepresented racial and ethnic groups. The
St. Louis Cord Blood Bank (SLCBB) began participating in this
program in September of 2007. The focus for our bank in achiev-
ing the goal of diversification was to establish strategies for re-
cruiting African American donors. Historically, this ethnic
group has not widely participated in cord blood donation in the
St. Louis area. A pilot study was instituted by the SLCBB at
SSM St. Mary’s Health Center in October of 2007. This hospital
was chosen due to its diverse patient population. We hypothe-
sized that the insertion of a dedicated staff nurse into this facility,
to educate and communicate directly with potential donors,
would result in a significant increase in donations from African
Americans. The results from this study are dramatic. A total of
448 cord blood units were collected during the study period (Oc-
tober 1, 2007 – September 30, 2008) as compared to 54 cord
blood units during the previous 12 month period (p 5
\0.0001). This equates to a 730% increase in African American
donations. This pilot study demonstrated that the SLCBB initia-
tive was successful not only in increasing the donation rate among
African Americans, but also an awareness of the life-saving bene-
fits of cord blood. While donations have increased at a significant
